Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pathway Genes
100%
Pancreatic Cancer
100%
Epidermal Growth Factor Receptor Signaling
100%
Gene Overexpression
100%
Inhibitor Sensitivity
100%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
100%
Tumor
28%
Overexpression
28%
Erlotinib
28%
Fluorescence in Situ Hybridization
14%
Gemcitabine
14%
Global Gene Expression Profiling
14%
MEK Inhibitor (MEKi)
14%
Cancer Tumor
14%
Treatment Response
14%
KRAS mutation
14%
EGFR mutation
14%
Core Genes
14%
Cetuximab
14%
Gene Amplification
14%
Drug Development
14%
Biological Characteristics
14%
Systems Biology Approach
14%
Genetic Abnormalities
14%
Pathway Activation
14%
Addiction
14%
Multiplex Ligation-dependent Probe Amplification
14%
Pathway-based Approach
14%
Predictive Factors
14%
Drug-resistant Tumor
14%
Gene Set Enrichment Analysis
14%
PIK3CA mutation
14%
PIK3CA Gene
14%
Analysi
14%
Medicine and Dentistry
Pancreas Cancer
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
100%
Gene Overexpression
100%
Tumor
50%
Erlotinib
25%
MEK Inhibitor
12%
Cetuximab
12%
Gene Expression Profiling
12%
Gemcitabine
12%
Fluorescence in Situ Hybridization
12%
Treatment Response
12%
Gene Amplification
12%
Multiplex Ligation Dependent Probe Amplification
12%
Addictive Behavior
12%
Anti-Epidermal Growth Factor Receptor
12%
Predictive Factor
12%
2 (2 Chloro 4 Iodoanilino) N Cyclopropylmethoxy 3,4 Difluorobenzamide
12%
Gene Structure
12%
Diseases
12%
Genome-Wide Analysis of Gene Expression
12%
Genetics
12%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Growth Factor Receptor Inhibitor
100%
Gene Overexpression
100%
Erlotinib
13%
MEK Inhibitor
6%
Genetics
6%
Fluorescence in Situ Hybridization
6%
Genetic Structure
6%
Gene Expression Profiling
6%
Gene Amplification
6%
Cetuximab
6%
KRAS
6%
Multiplex Ligation-Dependent Probe Amplification
6%
Gemcitabine
6%
Drug Development
6%
Genome-Wide Analysis of Gene Expression
6%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Pancreas Cancer
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Erlotinib
22%
Drug Development
11%
Gemcitabine
11%
Mitogen Activated Protein Kinase Kinase Inhibitor
11%
Cetuximab
11%
2 (2 Chloro 4 Iodoanilino) N Cyclopropylmethoxy 3,4 Difluorobenzamide
11%
Diseases
11%